Insilico Medicine, a clinical-stage generative artificial intelligence (AI)-driven drug discovery company, announced on Monday that it has entered into a research collaboration with pharmaceutical company Eli Lilly and Company (NYSE:LLY).

This partnership will combine Insilico's state-of-the-art Pharma.AI platforms with Lilly's development and disease expertise to jointly discover and advance innovative therapies.

Insilico will use its validated Pharma.AI platform and deep drug discovery expertise to generate, design, and optimise candidate compounds against targets defined. Insilico is eligible to receive over USD100m including an upfront, milestone payment, and tiered royalties on net sales on commercialisation of any resulting drug products.

Alex Zhavoronkov, PhD, Insilico Medicine founder and co-CEO, said: "Lilly has been a valued user of our Pharma.AI software suite, and this expanded collaboration further recognises Insilico's AI-driven drug discovery capabilities while strengthening our longstanding partnership. By joining forces, we are accelerating the development of transformative therapies to address urgent patient needs worldwide."